Gossamer Bio (GOSS) is a clinical-stage biopharmaceutical company with a pipeline of one drug: Seralutinib. Seralutinib is focused on treating pulmonary arterial hypertension ("PAH") and pulmonary hypertension with interstitial lung disease ("PH-ILD"). The company has a history of disappointing investors, typical in biotech, as 90% of drugs fail clinica…
Keep reading with a 7-day free trial
Subscribe to Microcap Opportunities to keep reading this post and get 7 days of free access to the full post archives.